-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology ELISA Platform: Opening a New Era of Efficient and Accurate Biological Detection
Author:
InnoModels
Release time:
2024-06-26
In the field of biotechnology, enzyme-linked immunosorbent assay (ELISA), as a highly efficient assay, plays a crucial role in the observation of reactivity between biologically active ligands. However, the results of ELISA assay are affected by various factors, such as sensitivity, specificity, precision and stability. In order to provide a more reliable and efficient ELISA service, InnoModels Biotechnology has developed an ELISA platform, which has demonstrated significant value in the field of scientific research and clinical diagnostics due to its unique advantages.
1、Advanced platform technology
InnoModels Bio's ELISA platform adopts a series of advanced biotechnology and detection methods to ensure the accuracy and reliability of the experimental results. The kits on the platform are based on unique monoclonal antibody technology, which can provide strong support for the specificity, sensitivity and batch-to-batch consistency of ELISA assays. In addition, the platform adopts advanced signal amplification technology and data analysis system to further improve the sensitivity and accuracy of the assay.
2. Strict quality control
InnoModels Biotechnology has strict quality control of ELISA platform. From the procurement of raw materials to the delivery of finished products, each step is subject to strict quality inspection and monitoring. In addition, the platform has established a perfect quality management system to ensure that each batch of kits meets the predetermined quality standards. This strict quality control makes InnoModels' ELISA platform stand out among similar products and win wide recognition.

3、Abundant Product Variety
InnoModels Bio's ELISA platform provides a rich and diverse product assortment, covering a wide range of reactive species such as human, rat, mouse, pig and so on. A wide range of kits are available on the platform, including cytokines, hormones, tumor markers, autoimmune disease detection and many other areas. These kits can meet the needs of different research fields and provide comprehensive technical support for researchers.
4、Customized service
InnoModels Biotechnology attaches great importance to the needs of customers and provides personalized customized services. Customers can choose the types and specifications of kits suitable for them according to their own research needs. In addition, the platform also provides exclusive customization services, including the development and production of customized kits for different diseases. This flexible service model enables the ELISA platform of InnoModels Biotechnology to better meet the needs of customers.
5、Professional technical support
InnoModels Biotechnology has a professional technical team with rich experience and expertise in ELISA testing. The team members are able to provide comprehensive technical support and solutions to help customers solve problems encountered during the experimental process. In addition, the platform also provides detailed experimental guidance and operation manuals to help customers better use the kits for experiments.
In conclusion, with its advantages of advanced technology, strict quality control, rich product range, customized services and professional technical support, the ELISA platform of InnoModels Biotechnology has demonstrated significant value in the field of scientific research and clinical diagnosis. In the future, with the continuous development and innovation of biotechnology, InnoModels' ELISA platform will continue to play an important role and make greater contributions to human health and life science research.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd